000893306 001__ 893306
000893306 005__ 20250813093259.0
000893306 0247_ $$2doi$$a10.1007/s11307-020-01546-0
000893306 0247_ $$2ISSN$$a1536-1632
000893306 0247_ $$2ISSN$$a1860-2002
000893306 0247_ $$2Handle$$a2128/28068
000893306 0247_ $$2pmid$$a33006028
000893306 0247_ $$2WOS$$aWOS:000574311700001
000893306 037__ $$aFZJ-2021-02680
000893306 082__ $$a570
000893306 1001_ $$0P:(DE-HGF)0$$aDietlein, Felix$$b0
000893306 245__ $$a[18F]-JK-PSMA-7 PET/CT Under Androgen Deprivation Therapy in Advanced Prostate Cancer
000893306 260__ $$aCham$$bSpringer Nature Switzerland$$c2021
000893306 3367_ $$2DRIVER$$aarticle
000893306 3367_ $$2DataCite$$aOutput Types/Journal article
000893306 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1625900993_16098
000893306 3367_ $$2BibTeX$$aARTICLE
000893306 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000893306 3367_ $$00$$2EndNote$$aJournal Article
000893306 520__ $$aPurpose: PSMA imaging is frequently used for monitoring of androgen deprivation therapy(ADT) in prostate cancer. In a previous study, [18F]-JK-PSMA-7 exhibited favorable propertiesfor tumor localization after biochemical recurrence. In this retrospective study, we evaluated theperformance of [18F]-JK-PSMA-7 under ADT.Procedures: We examined the performance of [18F]-JK-PSMA-7 in 70 patients (first cohort) withincreasing or detectable PSA values under ADT (PSA G 2 ng/ml for 21/70 patients). We furtheranalyzed 58 independent patients with PSA levels G 2 ng/ml under ADT, who were imaged with[68Ga]PSMA-11 or [18F]DCFPyL (second cohort). Finally, we compared detection rates between[18F]-JK-PSMA-7, [68Ga]PSMA-11, and [18F]DCFPyL.Results: In the first cohort, we detected [18F]-JK-PSMA-7-positive lesions in 63/70 patients. Inpatients with PSA levels ≥ 2 ng/ml, the detection rate was 100 % (49/49). In patients with PSA G 2ng/ml, the detection rate was significantly lower (66.7 %, 14/21, p = 9.7 × 10−5) and dropped from85.7%(12/14, PSA levels between 0.3 and 2.0 ng/ml) to 28.6%(2/7) for PSA levels G 0.3 ng/ml (p =1.73 × 10−2). In the second cohort (PSA G 2 ng/ml), the detection rate was 79.3 % (46/58) for[68Ga]PSMA-11 or [18F]DCFPyL. Again, the detection rate was significantly higher (p = 1.1 × 10−2)for patients with PSA levels between 0.3 and 2.0 ng/ml (87.0 %, 40/46) relative to those with PSAlevels G 0.3 ng/ml (50 %, 6/12). No significant difference was found between [18F]-JK-PSMA-7 and[68Ga]PSMA-11 or [18F]DCFPyL in patients with PSA levels G 2 ng/ml (p = 0.4295).Conclusion: [18F]-JK-PSMA-7 PET showed a high detection rate in patients with PSA levels ≥0.3 ng/ml under ADT. The lower PSA threshold of 0.3 ng/ml for high detection rates wasconsistent across the three PSMA ligands. Thus, PSMA imaging is suitable for clinical follow-upof patients with increasing PSA levels under ADT.
000893306 536__ $$0G:(DE-HGF)POF4-525$$a525 - Decoding Brain Organization and Dysfunction (POF4-525)$$cPOF4-525$$fPOF IV$$x0
000893306 542__ $$2Crossref$$i2020-10-01$$uhttps://creativecommons.org/licenses/by/4.0
000893306 542__ $$2Crossref$$i2020-10-01$$uhttps://creativecommons.org/licenses/by/4.0
000893306 588__ $$aDataset connected to CrossRef, Journals: juser.fz-juelich.de
000893306 7001_ $$0P:(DE-HGF)0$$aMueller, Peter$$b1
000893306 7001_ $$0P:(DE-HGF)0$$aKobe, Carsten$$b2
000893306 7001_ $$0P:(DE-Juel1)180330$$aEndepols, Heike$$b3$$ufzj
000893306 7001_ $$0P:(DE-HGF)0$$aHohberg, Melanie$$b4
000893306 7001_ $$0P:(DE-Juel1)185610$$aZlatopolskiy, Boris$$b5$$ufzj
000893306 7001_ $$0P:(DE-Juel1)169356$$aKrapf, Philipp$$b6$$ufzj
000893306 7001_ $$0P:(DE-HGF)0$$aHeidenreich, Axel$$b7
000893306 7001_ $$0P:(DE-Juel1)166419$$aNeumaier, Bernd$$b8$$ufzj
000893306 7001_ $$0P:(DE-Juel1)177611$$aDrzezga, Alexander$$b9$$ufzj
000893306 7001_ $$0P:(DE-HGF)0$$aDietlein, Markus$$b10$$eCorresponding author
000893306 77318 $$2Crossref$$3journal-article$$a10.1007/s11307-020-01546-0$$bSpringer Science and Business Media LLC$$d2020-10-01$$n2$$p277-286$$tMolecular Imaging and Biology$$v23$$x1536-1632$$y2020
000893306 773__ $$0PERI:(DE-600)2079211-6$$a10.1007/s11307-020-01546-0$$gVol. 23, no. 2, p. 277 - 286$$n2$$p277-286$$tMolecular imaging and biology$$v23$$x1536-1632$$y2021
000893306 8564_ $$uhttps://juser.fz-juelich.de/record/893306/files/Dietlein2021_Article_%5B18F%5D-JK-PSMA-7PETCTUnderAndro.pdf$$yOpenAccess
000893306 909CO $$ooai:juser.fz-juelich.de:893306$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000893306 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2020-10-13
000893306 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2020-10-13
000893306 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2020-10-13
000893306 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bMOL IMAGING BIOL : 2018$$d2020-10-13
000893306 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2020-10-13
000893306 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2020-10-13$$wger
000893306 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2020-10-13
000893306 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2020-10-13
000893306 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000893306 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2020-10-13
000893306 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2020-10-13
000893306 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2020-10-13
000893306 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2020-10-13
000893306 9141_ $$y2021
000893306 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)180330$$aForschungszentrum Jülich$$b3$$kFZJ
000893306 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)185610$$aForschungszentrum Jülich$$b5$$kFZJ
000893306 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)169356$$aForschungszentrum Jülich$$b6$$kFZJ
000893306 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)166419$$aForschungszentrum Jülich$$b8$$kFZJ
000893306 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)177611$$aForschungszentrum Jülich$$b9$$kFZJ
000893306 9131_ $$0G:(DE-HGF)POF4-525$$1G:(DE-HGF)POF4-520$$2G:(DE-HGF)POF4-500$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bKey Technologies$$lNatural, Artificial and Cognitive Information Processing$$vDecoding Brain Organization and Dysfunction$$x0
000893306 9130_ $$0G:(DE-HGF)POF3-573$$1G:(DE-HGF)POF3-570$$2G:(DE-HGF)POF3-500$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bKey Technologies$$lDecoding the Human Brain$$vNeuroimaging$$x0
000893306 920__ $$lyes
000893306 9201_ $$0I:(DE-Juel1)INM-5-20090406$$kINM-5$$lNuklearchemie$$x0
000893306 9201_ $$0I:(DE-Juel1)INM-2-20090406$$kINM-2$$lMolekulare Organisation des Gehirns$$x1
000893306 980__ $$ajournal
000893306 980__ $$aVDB
000893306 980__ $$aUNRESTRICTED
000893306 980__ $$aI:(DE-Juel1)INM-5-20090406
000893306 980__ $$aI:(DE-Juel1)INM-2-20090406
000893306 9801_ $$aFullTexts
000893306 999C5 $$1M Dietlein$$2Crossref$$9-- missing cx lookup --$$a10.1007/s11307-015-0866-0$$p575 -$$tMol Imaging Biol$$uDietlein M, Kobe C, Kuhnert G, Stockter S, Fischer T, Schomäcker K, Schmidt M, Dietlein F, Zlatopolskiy BD, Krapf P, Richarz R, Neubauer S, Drzezga A, Neumaier B (2015) Comparison of [(18)F]DCFPyL and [(68)Ga]Ga-PSMA-HBED-CC for PSMA-PET imaging in patients with relapsed prostate cancer. Mol Imaging Biol 17:575–584$$v17$$y2015
000893306 999C5 $$1F Dietlein$$2Crossref$$9-- missing cx lookup --$$a10.2967/jnumed.116.185538$$p947 -$$tJ Nucl Med$$uDietlein F, Kobe C, Neubauer S, Schmidt M, Stockter S, Fischer T, Schomäcker K, Heidenreich A, Zlatopolskiy BD, Neumaier B, Drzezga A, Dietlein M (2017) PSA-stratified performance of (18)F- and (68)Ga-PSMA PET in patients with biochemical recurrence of prostate cancer. J Nucl Med 58:947–952$$v58$$y2017
000893306 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.2967/jnumed.119.234898$$uDietlein F, Kobe C, Hohberg M et al (2020) Intraindividual comparison of 18F-PSMA-1007 with renally excreted PSMA ligands for PSMA-PET imaging in patients with relapsed prostate cancer. J Nucl Med 61:729–734
000893306 999C5 $$1FL Giesel$$2Crossref$$9-- missing cx lookup --$$a10.1007/s00259-016-3573-4$$p678 -$$tEur J Nucl Med Mol Imaging$$uGiesel FL, Hadaschik B, Cardinale J, Radtke J, Vinsensia M, Lehnert W, Kesch C, Tolstov Y, Singer S, Grabe N, Duensing S, Schäfer M, Neels OC, Mier W, Haberkorn U, Kopka K, Kratochwil C (2017) F-19 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Eur J Nucl Med Mol Imaging 44:678–688$$v44$$y2017
000893306 999C5 $$1BD Zlatopolskiy$$2Crossref$$9-- missing cx lookup --$$a10.2967/jnumed.118.218495$$p817 -$$tJ Nucl Med$$uZlatopolskiy BD, Endepols H, Krapf P, Guliyev M, Urusova EA, Richarz R, Hohberg M, Dietlein M, Drzezga A, Neumaier B (2019) Discovery of 18F-JK-PSMA-7, a novel PET-probe for the detection of small PSMA positive lesions. J Nucl Med 60:817–823$$v60$$y2019
000893306 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1186/s13550-019-0540-7$$uHohberg M, Dietlein M, Kobe C et al (2019) Biodistribution and radiation dosimetry of the novel 18F-labeled prostate-specific membrane antigen-ligand PSMA-7 for PET/CT in prostate cancer patients. Ejnmmi Res 9(1):66. https://doi.org/10.1186/s13550-019-0540-7
000893306 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.2967/jnumed.119.229542$$uDietlein F, Hohberg M, Kobe C et al (2020) An 18F-labeled PSMA ligand for PET/CT imaging of prostate cancer: first-in-humans observational study and clinical experience with 18F-JK-PSMA-7 during the first year of application. J Nucl Med 61:202–209
000893306 999C5 $$2Crossref$$uMorret N, van den Bergh RCN, Briers E et al (2018) EAU-ESTRO-ESUR-SIOG guidelines on prostate cancer. European Association of Urology 2018; uroweb.org; last access on 2019, Oct 09
000893306 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1158/1078-0432.CCR-19-1050$$uFendler WP, Weber M, Iravani A et al (2019) Prostate-specific membrane antigen ligand positron-emission tomography in men with nonmetastatic castration-resistant prostate cancer. Clin Cancer Res in press. https://doi.org/10.1158/1078-0432.CCR-19-1050
000893306 999C5 $$1L Emmett$$2Crossref$$9-- missing cx lookup --$$a10.2967/jnumed.118.223099$$p950 -$$tJ Nucl Med$$uEmmett L, Yin C, Crumbaker M, Hruby G, Kneebone A, Epstein R, Nguyen Q, Hickey A, Ihsheish N, O’Neill G, Horvath L, Chalasani V, Stricker P, Joshua AM (2019) Rapid modulation of PSMA expression by androgen deprivation: serial 68Ga-PSMA-11 PET in men with hormone-sensitive and castrate-resistant prostate cancer commencing androgen blockade. J Nucl Med 60:950–954$$v60$$y2019
000893306 999C5 $$1A Afshar-Oromieh$$2Crossref$$9-- missing cx lookup --$$a10.1007/s00259-018-4079-z$$p2045 -$$tEur J Nucl Med Mol Imaging$$uAfshar-Oromieh A, Debus N, Uhrig M et al (2019) Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer. Eur J Nucl Med Mol Imaging 45:2045–2054$$v45$$y2019
000893306 999C5 $$1C Leitsmann$$2Crossref$$9-- missing cx lookup --$$a10.1590/s1677-5538.ibju.2018.0305$$p459 -$$tInt Braz J Urol$$uLeitsmann C, Thelen P, Schmid M, Meller J, Sahlmann CO, Meller B, Trojan L, Strauss A (2019) Enhancing PSMA-uptake with androgen deprivation therapy – a new way to detect prostate cancer metastases? Int Braz J Urol 45:459–467$$v45$$y2019
000893306 999C5 $$1M Eiber$$2Crossref$$9-- missing cx lookup --$$a10.2967/jnumed.117.198119$$p469 -$$tJ Nucl Med$$uEiber M, Herrmann K, Calais J, Hadaschik B, Giesel FL, Hartenbach M, Hope T, Reiter R, Maurer T, Weber WA, Fendler WP (2018) Prostate cancer molecular imaging standardized evaluation (PROMISE): Proposed miTNM classification for the interpretation of PSMA-ligand PET/CT. J Nucl Med 59:469–478$$v59$$y2018
000893306 999C5 $$1SP Rowe$$2Crossref$$9-- missing cx lookup --$$a10.2967/jnumed.117.195255$$p479 -$$tJ Nucl Med$$uRowe SP, Pienta KJ, Pomper MG, Gorin MA (2018) Proposal for a structured reporting system for prostate-specific membrane antigen-targeted PET imaging: PSMA-RADS version 1.0. J Nucl Med 59:479–485$$v59$$y2018
000893306 999C5 $$1F Ceci$$2Crossref$$9-- missing cx lookup --$$a10.1007/s00259-019-04505-2$$p136 -$$tEur J Nucl Med Mol Imaging$$uCeci F, Bianch L, Borghesi et al (2020) Prediction nomogram for 68Ga-PSMA-11 PET/CT in different clinical settings of PSA failure after radical treatment of prostate cancer. Eur J Nucl Med Mol Imaging 47:136–146$$v47$$y2020
000893306 999C5 $$1C Onal$$2Crossref$$9-- missing cx lookup --$$a10.1007/s00259-019-04581-4$$p632 -$$tEur J Nucl Med Mol Imaging$$uOnal C, Guler OC, Torun N, Reyhan M, Yapar AF (2020) The effect of androgen deprivation on 68Ga-PSMA tracer uptake in non-metastatic prostate cancer patients. Eur J Nucl Med Mol Imaging 47:632–641$$v47$$y2020
000893306 999C5 $$1O Ettala$$2Crossref$$9-- missing cx lookup --$$a10.1007/s00259-019-04635-7$$p665 -$$tEur J Nucl Med Mol Imaging$$uEttala O, Malaspina S, Tuokkola T, Luoto P, Löyttyniemi E, Boström PJ, Kemppainen J (2020) Prospective study on the effect of short-term androgen deprivation therapy on PSMA uptake evaluated with 68Ga-PSMA-11 PET/MRI in men with treatment-naïve prostate cancer. Eur J Nucl Med Mol Imaging 47:665–673$$v47$$y2020
000893306 999C5 $$1M Wondergem$$2Crossref$$9-- missing cx lookup --$$a10.1097/RLU.0000000000002585$$p582 -$$tClin Nucl Med$$uWondergem M, van der Zant F, Broos W, Knol R (2019) Increased PSMA expression in castration-resistant prostate cancer metastases 3 months after initiation of enzalutamide indicated by 18F-DCFPyL PET/CT. Clin Nucl Med 44:582–584$$v44$$y2019
000893306 999C5 $$1F Rosar$$2Crossref$$9-- missing cx lookup --$$a10.1007/s00259-019-04674-0$$p687 -$$tEur J Nucl Med Mol Imaging$$uRosar F, Dewes S, Ries M, Schaefer A, Khreish F, Maus S, Bohnenberger H, Linxweiler J, Bartholomä M, Ohlmann C, Ezziddin S (2020) New insights in the paradigm of upregulation of tumoral PSMA expression by androgen receptor blockade: enzalutamide induces PSMA upregulation in castrate-resistant prostate cancer even in patients having previously progressed on enzalutamide. Eur J Nucl Med Mol Imaging 47:687–694$$v47$$y2020
000893306 999C5 $$1S Vaz$$2Crossref$$9-- missing cx lookup --$$a10.1007/s00259-019-04529-8$$p9 -$$tEur J Nucl Med Mol Imaging$$uVaz S, Hadaschik B, Gabriel M, Herrmann K, Eiber M, Costa D (2020) Influence of androgen deprivation therapy on PSMA expression and PSMA-ligand PET imaging of prostate cancer patients. Eur J Nucl Med Mol Imaging 47:9–15$$v47$$y2020
000893306 999C5 $$1ID Davis$$2Crossref$$9-- missing cx lookup --$$a10.1056/NEJMoa1903835$$p121 -$$tN Engl J Med$$uDavis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, Coskinas X, Frydenberg M, Hague WE, Horvath LG, Joshua AM, Lawrence NJ, Marx G, McCaffrey J, McDermott R, McJannett M, North SA, Parnis F, Parulekar W, Pook DW, Reaume MN, Sandhu SK, Tan A, Tan TH, Thomson A, Tu E, Vera-Badillo F, Williams SG, Yip S, Zhang AY, Zielinski RR, Sweeney CJ, ENZAMET Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (2019) Enzalutamide with standrad first-line therapy in metastastic prostate cancer. N Engl J Med 381:121–131$$v381$$y2019